ArticleOncogene2000
Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation.
Article in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 77 citations in OpenAlex.
- Systematic analysis of breast atypical hyperplasia-associated hub genes and pathways based on text mining.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2019Article
- Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.Cancer discovery · 2018Article
- Mammary epithelial cell phenotype disruption in vitro and in vivo through ERalpha36 overexpression.PloS one · 2017Article
- Cell type of origin as well as genetic alterations contribute to breast cancer phenotypes.Oncotarget · 2015Article
- Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis.Breast cancer research : BCR · 2014Article
- Metformin and erlotinib synergize to inhibit basal breast cancer.Oncotarget · 2014Article
- When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase.Cells · 2014Article
- Genetically engineered mice as experimental tools to dissect the critical events in breast cancer.Advances in cancer research · 2014Review
- Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways.Breast cancer research and treatment · 2012Article
- Article
- Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor.Journal of cell science · 2011Article
- Article
- Oncogenes and tumor suppressor genes.Cold Spring Harbor perspectives in biology · 2010Review
- Mammary gland growth factors: roles in normal development and in cancer.Cold Spring Harbor perspectives in biology · 2010Review
- EGFR/Met association regulates EGFR TKI resistance in breast cancer.Journal of molecular signaling · 2010Article
- Epidermal growth factor signalling and bone metastasis.British journal of cancer · 2010Review
- Mammary involution and breast cancer risk: transgenic models and clinical studies.Journal of mammary gland biology and neoplasia · 2009Review
- Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop.Cellular signalling · 2009Article
- The ADAM17-amphiregulin-EGFR axis in mammary development and cancer.Journal of mammary gland biology and neoplasia · 2008Review
- The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.The Journal of clinical investigation · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidermal growth factor receptor (EGFR) is overexpressed in about 48% of human breast cancer tissues. To analyse the role of the EGFR in mammary tumor development we generated transgenic mice expressing the human EGFR under the control of either the MMTV-LTR (MHERc) or the beta-lactoglobulin promoter (BLGHERc). The BLGHERc-transgene was expressed exclusively in the female mammary gland, whereas the MHERc transgene was expressed more promiscuously in other organs, such as ovary, salivary gland and testis. Female virgin and lactating transgenic mice of both strains have impaired mammary gland development. Virgin EGFR transgenic mice developed mammary epithelial hyperplasias, whereas in lactating animals progression to dysplasias and tubular adenocarcinomas was observed. In both strains the number of dysplasias increased after multiple pregnancies. The transgene expression pattern was heterogeneous, but generally restricted to regions of impaired mammary gland development. Highest EGFR transgene expression was observed in adenocarcinomas. By using a whole mount organ culture system to study the differentiation potential of the mammary epithelium, we observed a reduced number of fully developed alveoli and a decrease in whey acidic protein expression. Taken together, EGFR overexpression results in a dramatic effect of impaired mammary gland development in vitro as well as in vivo, reducing the differentiation potential of the mammary epithelium and inducing epithelial cell transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.